
Novo Nordisk’s Wegovy hits australian market
Novo Nordisk’s Wegovy, a popular weight loss drug, is scheduled for an August release in Australia, making it the 12th country to offer the medication. Whilst the drug will require a prescription, it won’t be subsidized, as reported by Australian Financial Review. After its Danish debut in 2022, around 120,000 Danes have used Wegovy. The drug recently entered Spain and Canada, and is also available in the US, Japan and several other nations. Novo Nordisk has just secured approval for Wegovy in China, a market expected to become its second-largest after the US, although the rollout will be limited initially. The company’s presence in China includes diabetes treatment Ozempic, which earned over 4.8 billion DKK last year. Both Wegovy and Ozempic are based on semaglutide, which reduces blood sugar, appetite, and body fat.